DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Ottawa Marriott Hotel

2017年10月17日 (火) 午前 7:00 - 2017年10月18日 (水) 午後 3:00

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

DIA Annual Canadian Meeting

Session 5A: Clinical Trial and Data Transparency

Session Chair(s)

Lorella  Garofalo, PhD

Lorella Garofalo, PhD

Head of Regulatory Sciences

Pfizer Canada ULC, Canada

Increased transparency in research and regulatory decision making is a global growing trend. Regulatory authorities are adopting transparency policies that include requirements for disclosure of clinical trial information and data. In addition, research organizations have also implemented initiatives to make data more widely available. This session will provide an overview of Health Canada’s proposal to publicly release clinical information as well as the efforts undertaken by other groups to make data available to the broader research community. Implications for study participant confidentiality, compliance with privacy regulations in multiple jurisdictions and other legal considerations for data disclosure will also be discussed.

Speaker(s)

Andre  Molgat, PhD

Health Canada’s Regulatory Proposal and Policy on the Public Release of Clinical Information in Drug Submissions and Medical Device Applications

Andre Molgat, PhD

Health Canada, Canada

Head of Operations, Public Release of Clinical Information

Yolande  Dufresne

Legal Considerations with Disclosure of Clinical Data

Yolande Dufresne

TORYS, LLP, Canada

Refik  Saskin

Accessing Health Administrative Data Through ICES Data & Analytic Services

Refik Saskin

Institute for Clinical Evaluation Sciences (ICES), Canada

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。